Comparative biochemical analysis of recombinant reverse transcriptase enzymes of HIV-1 subtype B and subtype C

Retrovirology

Volumn 7, Issue , 2010, Pages

  Xu, Hong Tao ^a   Quan, Yudong ^a   Asahchop, Eugene ^a   Oliveira, Maureen ^a   Moisi, Daniella ^a   Wainberg, Mark A ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; LAMIVUDINE; NEVIRAPINE; PRIMER DNA; RECOMBINANT ENZYME; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; SINGLE STRANDED DNA; TENOFOVIR; TRANSFER RNA; ZIDOVUDINE; RECOMBINANT PROTEIN; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1; RNA DIRECTED DNA POLYMERASE INHIBITOR;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CELL FREE SYSTEM; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SYNTHESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME PURIFICATION; ESCHERICHIA COLI; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; VIRUS CULTURE; CELL CULTURE; CLASSIFICATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; VIROLOGY;

CERCOPITHECINE HERPESVIRUS 1; ESCHERICHIA COLI; HUMAN IMMUNODEFICIENCY VIRUS 1;

CELLS, CULTURED; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEASE H; RNA-DIRECTED DNA POLYMERASE;

EID: 77957377561     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-80     Document Type: Article

References (45)

1. Rambaut A, Posada D, Crandall KA, Holmes EC. The causes and consequences of HIV evolution. Nat Rev Genet 2004, 5:52-61. 10.1038/nrg1246, 14708016.
2. Robertson DL, Anderson JP, Bradac JA, Carr JK, Foley B, Funkhouser RK, Gao F, Hahn BH, Kalish ML, Kuiken C, et al. HIV-1 nomenclature proposal. Science 2000, 288:55-56. 10.1126/science.288.5463.55d, 10766634.
3. Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how?. Lancet 2000, 355:2061-2066. 10.1016/S0140-6736(00)02360-6, 10885368.
4. Hemelaar J, Gouws E, Ghys PD, Osmanov S. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS 2006, 20:W13-23. 10.1097/01.aids.0000247564.73009.bc, 17053344.
5. Goff SP. Retroviral reverse transcriptase: synthesis, structure, and function. J Acquir Immune Defic Syndr 1990, 3:817-831.
6. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987, 317:185-191. 10.1056/NEJM198707233170401, 3299089.
7. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790. 10.1126/science.1377403, 1377403.
8. Schultz SJ, Champoux JJ. RNase H activity: structure, specificity, and function in reverse transcription. Virus Res 2008, 134:86-103. 10.1016/j.virusres.2007.12.007, 2464458, 18261820.
9. Tramontano E, Esposito F, Badas R, Di Santo R, Costi R, La Colla P. 6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. Antiviral Res 2005, 65:117-124. 10.1016/j.antiviral.2004.11.002, 15708638.
10. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009, 17:138-145.
11. Sarafianos SG, Marchand B, Das K, Himmel DM, Parniak MA, Hughes SH, Arnold E. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 2009, 385:693-713. 10.1016/j.jmb.2008.10.071, 2881421, 19022262.
12. Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS 2006, 20:F9-13. 10.1097/01.aids.0000232228.88511.0b, 16816549.
13. Gupta RK, Chrystie IL, O'Shea S, Mullen JE, Kulasegaram R, Tong CY. K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients. AIDS 2005, 19:1916-1919. 10.1097/01.aids.0000189860.36688.e5, 16227803.
14. Invernizzi CF, Coutsinos D, Oliveira M, Moisi D, Brenner BG, Wainberg MA. Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis 2009, 200:1202-1206. 10.1086/605894, 19764886.
15. Martinez-Cajas JL, Pant-Pai N, Klein MB, Wainberg MA. Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev 2008, 10:212-223.
16. Gonzales MJ, Machekano RN, Shafer RW. Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001, 184:998-1006. 10.1086/323601, 2597357, 11574914.
17. Le Grice SF, Gruninger-Leitch F. Rapid purification of homodimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 1990, 187:307-314. 10.1111/j.1432-1033.1990.tb15306.x, 1688798.
18. Stahlhut MW, Olsen DB. Expression and purification of retroviral HIV-1 reverse transcriptase. Methods Enzymol 1996, 275:122-133. full_text, 9026635.
19. Maier G, Dietrich U, Panhans B, Schroder B, Rubsamen-Waigmann H, Cellai L, Hermann T, Heumann H. Mixed reconstitution of mutated subunits of HIV-1 reverse transcriptase coexpressed in Escherichia coli - two tags tie it up. Eur J Biochem 1999, 261:10-18. 10.1046/j.1432-1327.1999.00304.x, 10103027.
20. Pandey VN, Kaushik N, Rege N, Sarafianos SG, Yadav PN, Modak MJ. Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function and fidelity of DNA synthesis. Biochemistry 1996, 35:2168-2179. 10.1021/bi9516642, 8652558.
21. Stahlhut M, Li Y, Condra JH, Fu J, Gotlib L, Graham DJ, Olsen DB. Purification and characterization of HIV-1 reverse transcriptase having a 1:1 ratio of p66 and p51 subunits. Protein Expr Purif 1994, 5:614-621. 10.1006/prep.1994.1084, 7532052.
22. Held DM, Kissel JD, Thacker SJ, Michalowski D, Saran D, Ji J, Hardy RW, Rossi JJ, Burke DH. Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers. J Virol 2007, 81:5375-5384. 10.1128/JVI.01923-06, 1900219, 17329328.
23. Le Grice SF, Cameron CE, Benkovic SJ. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol 1995, 262:130-144. full_text, 8594344.
24. Kim B, Hathaway TR, Loeb LA. Fidelity of mutant HIV-1 reverse transcriptases: interaction with the single-stranded template influences the accuracy of DNA synthesis. Biochemistry 1998, 37:5831-5839. 10.1021/bi972672g, 9558316.
25. Kim B, Ayran JC, Sagar SG, Adman ET, Fuller SM, Tran NH, Horrigan J. New human immunodeficiency virus, type 1 reverse transcriptase (HIV-1 RT) mutants with increased fidelity of DNA synthesis. Accuracy, template binding, and processivity. J Biol Chem 1999, 274:27666-27673. 10.1074/jbc.274.39.27666, 10488107.
26. Fleury HJ, Toni T, Lan NT, Hung PV, Deshpande A, Recordon-Pinson P, Boucher S, Lazaro E, Jauvin V, Lavignolle-Aurillac V, et al. Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses 2006, 22:357-366. 10.1089/aid.2006.22.357, 16623640.
27. Diallo K, Marchand B, Wei X, Cellai L, Gotte M, Wainberg MA. Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J Virol 2003, 77:8621-8632. 10.1128/JVI.77.16.8621-8632.2003, 167213, 12885880.
28. Wei X, Liang C, Gotte M, Wainberg MA. The M184V mutation in HIV-1 reverse transcriptase reduces the restoration of wild-type replication by attenuated viruses. AIDS 2002, 16:2391-2398. 10.1097/00002030-200212060-00003, 12461412.
29. Back NK, Nijhuis M, Keulen W, Boucher CA, Oude Essink BO, van Kuilenburg AB, van Gennip AH, Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996, 15:4040-4049. 452124, 8670908.
30. Caliendo AM, Savara A, An D, DeVore K, Kaplan JC, D'Aquila RT. Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. J Virol 1996, 70:2146-2153. 190052, 8642636.
31. Ball SC, Abraha A, Collins KR, Marozsan AJ, Baird H, Quinones-Mateu ME, Penn-Nicholson A, Murray M, Richard N, Lobritz M, et al. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J Virol 2003, 77:1021-1038. 10.1128/JVI.77.2.1021-1038.2003, 140829, 12502818.
32. Marozsan AJ, Moore DM, Lobritz MA, Fraundorf E, Abraha A, Reeves JD, Arts EJ. Differences in the fitness of two diverse wild-type human immunodeficiency virus type 1 isolates are related to the efficiency of cell binding and entry. J Virol 2005, 79:7121-7134. 10.1128/JVI.79.11.7121-7134.2005, 1112120, 15890952.
33. Diallo K, Gotte M, Wainberg MA. Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2003, 47:3377-3383. 10.1128/AAC.47.11.3377-3383.2003, 253767, 14576091.
34. Wendeler M, Lee HF, Bermingham A, Miller JT, Chertov O, Bona MK, Baichoo NS, Ehteshami M, Beutler J, O'Keefe BR, et al. Vinylogous ureas as a novel class of inhibitors of reverse transcriptase-associated ribonuclease H activity. ACS Chem Biol 2008, 3:635-644. 10.1021/cb8001039, 2941776, 18831589.
35. Ehteshami M, Gotte M. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 2008, 10:224-235.
36. Coutsinos D, Invernizzi CF, Xu H, Moisi D, Oliveira M, Brenner BG, Wainberg MA. Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol 2009, 83:2029-2033. 10.1128/JVI.01349-08, 2643749, 19073730.
37. Harrigan PR, Sheen CW, Gill VS, Wynhoven B, Hudson E, Lima VD, Lecocq P, Aguirre R, Poon AF, Sluis-Cremer N. Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency. AIDS 2008, 22:2501-2508. 10.1097/QAD.0b013e328318f16c, 19005273.
38. Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 2010,
39. Lisovsky I, Schader SM, Martinez-Cajas JL, Oliveira M, Moisi D, Wainberg MA. HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes. Antimicrob Agents Chemother 2010, 54:2878-2885. 10.1128/AAC.01828-09, 20404123.
40. Arts EJ, Li X, Gu Z, Kleiman L, Parniak MA, Wainberg MA. Comparison of deoxyoligonucleotide and tRNA(Lys-3) as primers in an endogenous human immunodeficiency virus-1 in vitro reverse transcription/template-switching reaction. J Biol Chem 1994, 269:14672-14680.
41. Xu HT, Martinez-Cajas JL, Ntemgwa ML, Coutsinos D, Frankel FA, Brenner BG, Wainberg MA. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 2009, 6:14. 2644664, 19210791.
42. Quan Y, Brenner BG, Marlink RG, Essex M, Kurimura T, Wainberg MA. Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses 2003, 19:743-753. 10.1089/088922203769232548, 14585205.
43. Sharma PL, Crumpacker CS. Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val. J Virol 1999, 73:8448-8456. 112864, 10482597.
44. Gopalakrishnan V, Peliska JA, Benkovic SJ. Human immunodeficiency virus type 1 reverse transcriptase: spatial and temporal relationship between the polymerase and RNase H activities. Proc Natl Acad Sci USA 1992, 89:10763-10767. 10.1073/pnas.89.22.10763, 50422, 1279694.
45. Operario DJ, Balakrishnan M, Bambara RA, Kim B. Reduced dNTP interaction of human immunodeficiency virus type 1 reverse transcriptase promotes strand transfer. J Biol Chem 2006, 281:32113-32121. 10.1074/jbc.M604665200, 16926150.